Skip to content
imbria logo (1)
  • Company
    • Mission & Values
    • Our Team
    • Board of Directors
    • Investors
    • Contact
  • Science & Pipeline
    • Pipeline
    • Ninerafaxstat
    • Publications & Presentations
  • Patients & Families
    • nHCM
    • HFpEF
    • Clinical Trials
      • Expanded Access Policy
  • Investors & Media
    • Press Releases
imbria logo (1)
  • Company
    • Mission & Values
    • Our Team
    • Board of Directors
    • Investors
    • Contact
  • Science & Pipeline
    • Pipeline
    • Ninerafaxstat
    • Publications & Presentations
  • Patients & Families
    • nHCM
    • HFpEF
    • Clinical Trials
      • Expanded Access Policy
  • Investors & Media
    • Press Releases

Press Releases

Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

June 24, 2026
Read More »

Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac Energetics in Cardiometabolic Disease

January 7, 2026
Read More »

Imbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular Diseases

November 17, 2025
Read More »

Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy

November 6, 2025
Read More »

Imbria Pharmaceuticals Partners with Hypertrophic Cardiomyopathy Association to Support FORTITUDE-HCM Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy

October 16, 2025
Read More »

Imbria Pharmaceuticals Strengthens Leadership with New Board and Key Clinical Appointments

September 16, 2025
Read More »
Page1 Page2 Page3 Page4 Page5
  • Company
  • Science & Pipeline
  • Patients & Families
  • Investors & Media
  • Company
  • Science & Pipeline
  • Patients & Families
  • Investors & Media
CONTACT

Privacy Policy      Terms of Use

2025 © Imbria Pharmaceuticals​

Linkedin